New chalcone derivatives as effective against SARS-CoV-2 agent

ArticleAçık Erişim

Özet

Aims: Flavonoids and related compounds, such as quercetin-based antiviral drug Gene-Eden-VIR/Novirin, inhibit the protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The alkylated chalcones isolated from Angelica keiskei inhibit SARS-CoV proteases. In this study, we aimed to compare the anti-SARS CoV-2 activities of both newly synthesized chalcone derivatives and these two drugs. Methods: Determination of the potent antiviral activity of newly synthesized chalcone derivatives against SARS-CoV-2 by calculating the RT-PCR cycling threshold (Ct) values. Results: Antiviral activities of the compounds varied because of being dose dependent. Compound 6, 7, 9, and 16 were highly effective against SARS-CoV-2 at the concentration of 1.60 µg/mL. Structure-based virtual screening was carried out against the most important druggable SARS-CoV-2 targets, viral RNA-dependent RNA polymerase, to identify putative inhibitors that could facilitate the development of potential anti-coronavirus disease-2019 drug candidates. Conclusions: Computational analyses identified eight compounds inhibiting each target, with binding affinity scores ranging from −4.370 to −2.748 kcal/mol along with their toxicological, ADME, and drug-like properties. © 2021 John Wiley & Sons Ltd

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/13162Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.1111/ijcp.14846Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorDuran, Nizami
dc.contributor.authorPolat, M. Fatih
dc.contributor.authorAktas, Derya Anil
dc.contributor.authorAlagoz, M. Abdullah
dc.contributor.authorAy, Emrah
dc.contributor.authorCimen, Funda
dc.contributor.authorTek, Erhan
dc.contributor.authorAnil, Baris
dc.contributor.authorBurmaoglu, Serdar
dc.contributor.authorAlgul, Oztekin
dc.date.accessioned2026-10-18T20:28:00.213594397Z
dc.date.available2026-10-18T20:28:00.213594397Z
dc.date.issued2021
dc.description.abstractAims: Flavonoids and related compounds, such as quercetin-based antiviral drug Gene-Eden-VIR/Novirin, inhibit the protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The alkylated chalcones isolated from Angelica keiskei inhibit SARS-CoV proteases. In this study, we aimed to compare the anti-SARS CoV-2 activities of both newly synthesized chalcone derivatives and these two drugs. Methods: Determination of the potent antiviral activity of newly synthesized chalcone derivatives against SARS-CoV-2 by calculating the RT-PCR cycling threshold (Ct) values. Results: Antiviral activities of the compounds varied because of being dose dependent. Compound 6, 7, 9, and 16 were highly effective against SARS-CoV-2 at the concentration of 1.60 µg/mL. Structure-based virtual screening was carried out against the most important druggable SARS-CoV-2 targets, viral RNA-dependent RNA polymerase, to identify putative inhibitors that could facilitate the development of potential anti-coronavirus disease-2019 drug candidates. Conclusions: Computational analyses identified eight compounds inhibiting each target, with binding affinity scores ranging from −4.370 to −2.748 kcal/mol along with their toxicological, ADME, and drug-like properties. © 2021 John Wiley & Sons Ltd
dc.identifier.doi10.1111/ijcp.14846
dc.identifier.eissn1742-1241
dc.identifier.issn1368-5031
dc.identifier.issue12
dc.identifier.pmcidPMC8646589
dc.identifier.pmid34519118
dc.identifier.scopus2-s2.0-85115626984
dc.identifier.startpagee14846
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/13162
dc.identifier.volume75
dc.identifier.wosWOS:000698956100001
dc.language.isoen
dc.publisherJohn Wiley and Sons Inc
dc.relation.ispartofInternational Journal of Clinical Practice
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAntiviral Agents
dc.subjectChalcone
dc.subjectChalcones
dc.subjectCOVID-19
dc.subjectHumans
dc.subjectSARS-CoV-2
dc.subject1 (2,5 difluorophenyl) 3 (2,4,6 trimethoxyphenyl)prop 2 en 1 one
dc.subject1 (3 bromo 2 hydroxy 4,6 dimethoxyphenyl) 3 (2,5 difluorophenyl)prop 2 en 1 one
dc.subject1 (3 bromo 2 hydroxy 4,6 dimethoxyphenyl) 3 (3,5 difluorophenyl)prop 2 en 1 one
dc.subject1 (3 bromo 2 hydroxy 4,6 dimethoxyphenyl) 3 [2 fluoro 5 ( trifluoromethyl)phenyl]prop 2 en 1 one
dc.subject1 (3 bromo 2 hydroxy 4,6 dimethoxyphenyl) 3(2,4,5 trifluorophenyl)propprop 2 en 1 one
dc.subject1 (3 bromo 2 hydroxy 4,6 dimethoxyphenyl)ethan 1 one
dc.subject1 (3,5 difluorophenyl) 3 (2,4,6 trimethoxyphenyl)prop 2 en 1 one
dc.subject1 [2 fluoro 5 (trifluoromethyl)phenyl] 3 (2,4,6 trimethoxyphenyl)prop 2 en 1 one
dc.subject1 [3,5 bis(trifluoromethyl)phenyl] 3 (2,4,6 trimethoxyphenyl)prop 2 en 1 one
dc.subjectanti-SARS-CoV-2 agent
dc.subjectchalcone derivative
dc.subjectunclassified drug
dc.subjectvirus RNA
dc.subjectantivirus agent
dc.subjectantiviral activity
dc.subjectArticle
dc.subjectbinding affinity
dc.subjectcarbon nuclear magnetic resonance
dc.subjectcontrolled study
dc.subjectdose response
dc.subjectdrug efficacy
dc.subjectdrug isolation
dc.subjectdrug potency
dc.subjectdrug structure
dc.titleNew chalcone derivatives as effective against SARS-CoV-2 agent
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus37
rdl.citation.wos31
rdl.departmentDepartment of Pharmaceutical Basic Sciences, Faculty of Pharmacy, Erzincan Binali Yildirim University, Erzincan, Turkey. | Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Erzincan Binali Yildirim University, Erzincan, Turkey.
rdl.oa.statusgreen
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexPUBMED
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)